Why It Matters

University of Texas M.D. Anderson Cancer Center filed an $800,000 lobbying disclosure for the first quarter of 2026, but the filing lists no specific issues, no legislation, and no issue codes, leaving the public record bare on what the nation's largest cancer center was pressing Congress about.

MD Anderson operates in one of the most contested federal policy environments of any research institution in the country. The center depends heavily on NIH grants and Medicare reimbursements, both of which are under active pressure from the White House and Congress. A proposed 40 percent cut to the NIH budget for fiscal year 2026, combined with new Medicare site-neutral payment rules that took effect January 1, 2026, creates real financial exposure for a hospital that received an estimated $190 million in NIH funding in 2024. Prior filings make clear MD Anderson has been tracking these threats closely. This quarter's blank disclosure offers no window into whether that continues.

By the Numbers

The first-quarter 2026 filing reports $800,000 in lobbying expenditures, a sharp jump from the $100,000 reported in each of the two prior quarters.

The first-quarter spending pattern mirrors last year's, when MD Anderson also reported $900,000 in the first quarter before dropping significantly in subsequent quarters. Across eight filings dating back to mid-2024, the center has reported $2,310,000 in total lobbying expenditures.

The lobbying is conducted entirely in-house. Ed Miller is the sole registered lobbyist on the account. No congressional staff record was found for Miller, and no outside lobbying firms are retained.

The Agenda

This filing lists no specific issues lobbied, no legislation, and no issue codes. The disclosure is effectively blank beyond the dollar amount.

Prior filings offer the clearest available guide to what MD Anderson has been focused on. The third quarter 2025 and second quarter 2025 disclosures listed a detailed agenda that included:

  • Medicare site-of-service payment policy changes
  • The Cassidy-Hassan Senate framework for hospital site-neutral payments
  • Medicare reimbursements for cancer services
  • Medicare Advantage preauthorization and access issues
  • "White bagging" of pharmaceutical products
  • NIH and NCI funding levels
  • The reorganization of HHS and its underlying agencies
  • The impact of executive orders on NIH indirect costs
  • The future of ARPA-H
  • Federal grant terminations
  • DOGE's information website on grant recipients
  • Clinical trial design and patient access to drugs

Whether those issues remain active in this quarter is unknown from this filing alone.

Broader Context

The policy environment around cancer research funding has shifted considerably in the past year. A May 2025 report from the Senate Health, Education, Labor, and Pensions (HELP) Committee minority staff indicates NIH cancer research funding fell 31 percent in the first three months of 2025 compared to the same period in 2024. The Trump administration proposed cutting the NIH budget by nearly 40 percent for fiscal year 2026, and a plan to consolidate NIH's 27 institutes into 8 has been reported. As of mid-2025, approximately 2,300 NIH grants totaling nearly $3.8 billion had been terminated, including at least 160 clinical trials.

Congressional members have engaged directly with MD Anderson on these issues. Sen. John Cornyn (R-TX) praised the center's receipt of a $22 million ARPA-H ADAPT grant for colon cancer research in May 2025. Rep. Lizzie Fletcher (D-TX-7) highlighted in April 2026 that NIH research grants fund 391,000 jobs nationally, "many of them here in Houston." Rep. Chip Roy (R-TX-21) noted in October 2025 that MD Anderson was no longer accessible under certain insurance plans, calling it "a problem."

The center also drew scrutiny. In September 2025, the House Science, Space, and Technology Committee sent a letter to MD Anderson raising research security concerns after a postdoctoral researcher allegedly uploaded breast cancer vaccine research to a Chinese server and failed to disclose Chinese grant funding.

On Medicare policy, CMS finalized its 2026 Hospital Outpatient Prospective Payment System rule in November 2025, which includes site-neutrality changes effective January 1, 2026. Those changes directly affect how outpatient cancer services at hospital-affiliated facilities are reimbursed.

The Bottom Line

MD Anderson reported $800,000 in first-quarter 2026 lobbying, with nothing disclosed about what that money was spent on. The spending level is consistent with the same quarter last year and represents a significant increase from the two prior quarters. The center faces documented pressure on multiple fronts (NIH funding, Medicare reimbursement policy, and federal grant stability) that prior filings show it has been actively tracking. Whether this quarter's activity addresses those same concerns cannot be determined from the disclosure itself.

Access the Legis1 platform for comprehensive political news, data, and insights.